25663-65-4

Upstream product

• 72271-71-7 4-(4-butylphenyl)-4-oxobutanoic acid 
• 104-51-8 1-butylbenzene 

Downstream Products

• 145772-44-7 4-(4'-n-butylcyclohexyl)butanoic acid 
• 102684-57-1 4-(4-butylphenyl)butanol 
• 117279-67-1 4-(2-chlorophenyl)-2-[2-(4-n-butylphenyl)ethyl]-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 122854-64-2 4-(4-Butyl-phenyl)-butyraldehyde 
• 183129-94-4 {2-Amino-5-[2-(4-butyl-phenyl)-ethyl]-thiophen-3-yl}-(2-chloro-phenyl)-methanone 
• 117280-20-3 7-[2-(4-Butyl-phenyl)-ethyl]-5-(2-chloro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 117280-21-4 7-[2-(4-Butyl-phenyl)-ethyl]-5-(2-chloro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepine-2-thione 
• 183130-11-2 2-Amino-N-[5-[2-(4-butyl-phenyl)-ethyl]-3-(2-chloro-benzoyl)-thiophen-2-yl]-acetamide 
• 183130-55-4 N-[5-[2-(4-Butyl-phenyl)-ethyl]-3-(2-chloro-benzoyl)-thiophen-2-yl]-2-chloro-acetamide 
• 117280-22-5 [7-[2-(4-Butyl-phenyl)-ethyl]-5-(2-chloro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 
• 102684-56-0 4-(4-butylphenyl)butyl bromide 
• 127948-46-3 2-[2-(4-(4-butylphenyl)butyl)phenyl]-4,4-dimethyloxazoline 

Relevant academic research and scientific papers

Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: Pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (±)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]- 6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.

Leukotriene antagonists

A method for inhibiting the effects of LTB4 comprises administration of an effective amount of a compound represented by the following structural formula (I) STR1 wherein m is 1 or 2; n is 1, 2 or 3; p is 0, 1, or 2; R' is hydrogen or methyl; R is phenyl substituted with A, R1 and R2 wherein R1 and R2 are independently selected from either (1) (S)a --(CH2)b --(T)c --B wherein a is 0 or 1; b is 5 to 12; c is 0 or 1; S and T are independently sulfur, oxygen, or CH2 with the proviso that S or T are not sulfur when p is 1 or 2; and B is C1-4 alkyl, ethynyl, trifluoromethyl, or phenyl optionally monosubstituted with Br, Cl, CF3, C1-4 alkoxy, C1-4 alkyl, methylthio, or trifluoromethylthio; or (2) hydrogen bromo, chloro, methyl, trifluoromethyl, methoxy or nitro; and A is selected from (2) as defined above or a pharmaceutically acceptable salt thereof. Such methods are useful in the treatment of diseases in which LTB4 is a factor.

LEUKOTRIENE ANTAGONIST

The compounds represented by the following structural formula (I) STR1 wherein m is 1 or 2; n is 1, 2 or 3; R' is hydrogen or methyl; R is a radical selected from the group consisting of: STR2 wherein R. sub.1 is C 8 to C 13 alkyl, C 7 to C 12 alkoxy, C 7 to C 12 thioalkyl, C 10 to C 12 1-alkynyl, 11-dodecynyl, 1-trans-dodecenyl, 5-(4-acetyl-3-hydroxy-2-propylphenoxypentoxy, 2(Z), 5(Z)-undecadienyloxy, phenyl-C 4 to C. sub.10 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenylthio-C 3 to C 9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenyl-CH. dbd.CH--(CH 2) 2-8, phenyl-C 3 to C 9 alkoxy, trifluoromethyl-C 7 to C 12 alkyl, cyclohexyl-C 4 to C 10 alkyl or STR3 wherein each q is 0, 1, 2 or 3 but the sum of both q's does not exceed 3, and R 2 is hydrogen, bromo, chloro, methyl, trifluoromethyl, hydroxy, methoxy or nitro; or R 1 is hydrogen and R. sub.2 is C 8 to C 13 alkyl, C 7 to C 12 alkoxy, C 7 to C 12 thioalkyl, C 10 to C. sub.12 1-alkynyl, 11-dodecynyl, 1-trans-dodecenyl, 5-(4-acetyl-3-hydroxy-2-propylphenoxy(pentoxy, 2(Z), 5(Z)-undecadienyloxy, phenyl-C 4 to C. sub.10 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenylthio-C 3 to C 9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenyl-CH. dbd.CH--(CH 2) 2-8, phenyl-C 3 to C 9 alkoxy, trifluoromethyl-C 7 to C 12 alkyl, cyclohexyl-C 4 to C 10 alkyl or STR4 wherein each q is 0, 1, 2 or 3 but the sum of both q's does not exceed 3, and p is 0 or 1, with the proviso that R is not a thiophene radical and any of R 1 and R. sub.2 above are not thioalkyl or phenylthioalkyl when p is 1; and pharmaceutically acceptable salts thereof have been found to be leukotriene antagonists and useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.